Chronic Lower Back Pain Market Report 2026

The chronic lower back pain market size has grown steadily in recent years. It will grow from $8.04 billion in 2025 to $8.41 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to increasing aging population, rising prevalence of musculoskeletal disorders, growing sedentary lifestyles, higher incidence of workplace-related back injuries, expanded access to diagnostic imaging.

The chronic lower back pain market size is expected to see steady growth in the next few years. It will grow to $10.06 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing demand for non-invasive therapies, growing adoption of digital therapeutics, expansion of outpatient pain management services, rising focus on personalized medicine, increased investments in chronic pain research. Major trends in the forecast period include increasing adoption of multimodal pain management approaches, rising use of minimally invasive interventions, growing integration of digital pain monitoring tools, expansion of personalized treatment pathways, enhanced focus on non-opioid therapies.

Growth in the geriatric population is anticipated to drive the expansion of the chronic lower back pain market in the coming years. The geriatric population refers to individuals aged 65 years and above. Among this population, age-related neurodegenerative and musculoskeletal disorders such as arthritis and osteoarthritis tend to progress more rapidly, leading to weakness and persistent pain that contribute to chronic back pain and reduced physical activity. For instance, in May 2024, according to the Administration for Community Living, a US-based government agency, 17.3% of the population in 2022 was aged 65 or older, and this share is projected to rise to 22% by 2040. As a result, the increasing geriatric population is fueling growth in the chronic lower back pain market.

Major companies operating in the chronic lower back pain market are focusing on developing products that incorporate advanced technologies such as BurstDR SCS technology to provide improved treatment options for patients. BurstDR SCS technology is a proprietary spinal cord stimulation therapy that uses mild electrical pulses to modify pain signals as they travel from the spinal cord to the brain. For example, in May 2023, Abbott Laboratories, a US-based medical device company, received FDA approval for its spinal cord stimulation devices, including the Proclaim SCS Family and the Eterna SCS System, for the treatment of chronic back pain. These devices deliver Abbott’s proprietary BurstDR stimulation waveform, which is designed to more closely replicate the natural transmission of pain signals to the brain and address the emotional distress associated with pain, unlike traditional tonic stimulation.

In November 2023, Boston Scientific, a US-based biotechnology engineering company, acquired Relievant Medsystems Inc. for $850 million. This acquisition strengthens Boston Scientific’s chronic pain management portfolio by adding Relievant’s Intracept intraosseous nerve ablation system, which is specifically developed to treat vertebrogenic pain, a form of chronic lower back pain. Relievant Medsystems Inc. is a US-based medical equipment manufacturing company.

Major companies operating in the chronic lower back pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy's Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

North America was the largest region in the chronic lower back pain market in 2025. The regions covered in the chronic lower back pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic lower back pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic lower back pain market by increasing the cost of imported medical devices, imaging equipment, pain management instruments, and advanced therapeutic technologies used across hospitals and specialty clinics. North America and Europe are most affected due to reliance on imported diagnostic and interventional equipment, while Asia-Pacific faces cost pressure on device manufacturing and distribution. These tariffs are contributing to higher treatment costs and delayed technology upgrades in clinical settings. However, they are also encouraging domestic manufacturing of pain management devices, local sourcing of rehabilitation equipment, and regional innovation in cost-effective therapeutic solutions.

The chronic lower back pain market research report is one of a series of new reports that provides chronic lower back pain market statistics, including chronic lower back pain industry global market size, regional shares, competitors with a chronic lower back pain market share, detailed chronic lower back pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic lower back pain industry. This chronic lower back pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic low back pain (CLBP) is defined as pain that continues for 12 weeks or longer even after treatment of the underlying cause of acute low back pain or the initial injury. Chronic low back pain is a leading cause of disability and is commonly associated with psychological conditions such as stress, depression, and anxiety.

The primary types of chronic lower back pain include discogenic pain, lumbar spinal stenosis, sacroiliac pain, facet joint pain, radicular pain, muscular pain, and others. Discogenic pain is a type of low back pain caused by damage to a spinal disc, most often due to degenerative disc disease, which occurs naturally with aging. It is diagnosed through clinical history, physical examination, imaging guidelines, and pain assessment, and is treated across various healthcare settings such as hospitals, orthopedic clinics, ambulatory surgery centers, and others.

The chronic low back pain market includes revenues earned by entities by providing low back pain treatment services such as pain management services, and neuropathic and nociceptive pain management. Establishments that provide long treatment plans and management services are included in this market. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.